Geron (GERN)
(Delayed Data from NSDQ)
$4.32 USD
+0.01 (0.23%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.32 USD
+0.01 (0.23%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up
by Zacks Equity Research
Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.
Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron (GERN) Down 13% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Geron (GERN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 40.00% and -25.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
Geron (GERN) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Geron (GERN) closed at $1.72, marking a -0.58% move from the previous day.
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Geron's Stock Plunges as J&J Ends Imetelstat Collaboration
by Zacks Equity Research
Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.
Options Traders Expect Huge Moves in Geron (GERN) Stock
by Zacks Equity Research
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.
Geron Stock Up More Than 200% in 2018 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.
Why Is Geron (GERN) Up 58% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron's Growth Depends on Continuation of Imetelstat Studies
by Zacks Equity Research
Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.
Implied Volatility Surging for Geron (GERN) Stock Options
by Zacks Equity Research
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
by Zacks Equity Research
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
by Zacks Equity Research
Investors in Geron (GERN) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Geron (GERN) Stock Options
by Zacks Equity Research
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is Geron Corporation (GERN) Outperforming Other Medical Stocks This Year?
Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus continues to remain on its sole pipeline candidate, imetelstat, ahead of the first-quarter earnings release.
Is Geron Corporation (GERN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is Geron Corporation (GERN) Outperforming Other Medical Stocks This Year?
Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.